AstraZeneca Launches ZEGFROVY for Lung Cancer
The new oral medication treats adults with specific advanced non-small cell lung cancer mutations.
Updated on Oct. 31, 2026 in Cancer
Live Poll
Do you trust that new targeted cancer therapies significantly improve survival outcomes for most patients?
AstraZeneca has officially launched ZEGFROVY in the United States for adult patients with advanced non-small cell lung cancer. This treatment targets individuals with EGFR exon 20 insertion mutations who have already progressed following platinum-based chemotherapy.
Why it matters
This therapy addresses a specific lung cancer subtype that has historically proven difficult to manage with targeted treatments. It provides a new option for patients who have exhausted traditional chemotherapy methods.
The WU-KONG1B trial reported a 46% overall response rate among 85 study participants. Patients receiving the 200-milligram daily oral dose showed a median response duration of 11.1 months, with 72% maintaining their response for at least six months.
The players
AstraZeneca
This global pharmaceutical company develops and markets prescription medicines across several major disease areas including oncology and cardiovascular health.
Food and Drug Administration
This federal agency is responsible for protecting public health by regulating the safety, efficacy, and security of human drugs and biological products in the United States.
National Comprehensive Cancer Network
This not-for-profit alliance of leading cancer centers develops evidence-based clinical practice guidelines used to improve the quality and effectiveness of cancer care.
The details
The FDA granted accelerated approval for the drug based on tumor response data from the clinical trial. It is currently available to patients in the United States through specialty pharmacy networks and includes warnings for risks like pneumonitis.
Timeline
October 31, 2026: AstraZeneca launched the medication in the United States.
Health Landscape
The introduction of this therapy reflects the broader shift in oncology toward using the FDA's accelerated approval pathway to expedite access to targeted treatments. It follows the precedent established by other oncology drugs that rely on surrogate clinical endpoints to address high-need patient populations.
Patients with this specific lung cancer mutation now have access to a daily oral treatment that can be taken with food. Individuals should discuss potential side effects such as interstitial lung disease with their healthcare provider to manage care safely.
The takeaway
Patients who have progressed after initial chemotherapy now have a targeted daily treatment option. It remains essential for these individuals to continue monitoring their health as long-term confirmatory studies are completed.
Further reading
Learn more about new developments in oncology at the United States Cancer section.
Live Poll
Do you trust that new targeted cancer therapies significantly improve survival outcomes for most patients?
